AstraZeneca's Dobber On Ramping In Renal, Expanding In CV And Business Development
Executive Summary
Biopharmaceuticals President Ruud Dobber talked to Scrip about the launches of Lokelma and roxadustat in kidney disease, building with a high bar in cardiovascular disease and expanding in cell and gene therapy.